Geneva, May 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123936) titled 'A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of an Artificial Intelligence-Designed Tumor mRNA Vaccine in Patients With Advanced or Metastatic Solid Tumors' on May 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: West China Hospital, Sichuan University
Condition:
Patients with histologically confirmed, refractory advanced or metastatic malignant solid tumors who have failed second-line therapy and for whom no standard clinical treatment is available (e.g., patients with advanced soft tissue sarcoma, advanced head and neck squamous cell car...